[의약품]Depomed, Inc./ Grunenthal GMBH 대 Actavis Elizabeth, LLC/ Actavis, Inc./ ACTAVIS, LLC 간의 의약품 관련 특허 분쟁
발생일자 2015.09.11
사건번호 2:15-cv-06797
법원국가 UNITED STATES OF AMERICA
관할법원명 D.C.NewJersey(지방법원)
침해권리 특허
원고명 Depomed, Inc./ Grunenthal GMBH ( 미국 / 외국기업 )
피고명 Actavis Elizabeth, LLC/ Actavis, Inc./ ACTAVIS, LLC ( 미국 / 외국기업 )
소송유형 침해금지
분쟁내용
[Depomed, Inc. et al v. Actavis Elizabeth, LLC et al] 사건번호 2:15-cv-06797에 따르면 원고 Depomed, Inc./ Grunenthal GMBH는 피고 Actavis Elizabeth, LLC/ Actavis, Inc./ ACTAVIS, LLC을(를) 상대로 특허 US8536130을(를) 침해하였다는 이유로 미국 뉴저지 지방법원에 소를 제기하였다.
분쟁결과 분쟁중
산업분류 화학∙바이오 > 의약품
계쟁제품 Generic tapentadol hydrochloride extended release tablets in 50 mg, 100 mg, 150 mg, 200 mg and 250 mg dosages, generic versions of NUCYNTA® ER
지재권번호/명칭
US8536130 Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain
Abstract
Use of 1-phenyl-3-dimethylaminopropane compounds for the production of medicaments for treating neuropathic pain, preferably polyneuropathic pain, also preferably diabetic neuropathic pain, more preferably diabetic peripheral neuropathic pain, and furthermore preferably for treating diabetic peripheral neuropathy.
Claims
What is claimed is:
1. A method of treating polyneuropathic pain in a subject suffering therefrom, said method comprising administering to said subject an effective polyneuropathic pain inhibiting amount of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof.
2. A method according to claim 1, comprising administering a hydrochloride salt of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol.
3. A method according to claim 1, wherein said polyneuropathic pain is diabetic polyneuropathic pain.
4. A method according to claim 1, wherein said polyneuropathic pain is peripheral polyneuropathic pain.
5. A method according to claim 1, wherein said polyneuropathic pain is peripheral diabetic polyneuropathic pain.
6. A method of treating diabetic polyneuropathy in a subject suffering therefrom, said method comprising administering to said subject a pharmacologically effective amount of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof.
출처 ![[US Patent & Trademark Office, Patent Full Text and Image Database]](http://patft.uspto.gov/netaicon/PTO/patfthdr.gif)
